Successful development of a vaccine against HIV will require the induction of neutralizing antibody sufficient to prevent infection. Recent work analyzing HIV specific antibody responses from infected individuals has shown that broadly neutralizing antibodies are directed at several sites on the HIV Env. Moreover, several of these antibodies have unique characteristics such as a high rate of somatic mutation and/or long CDRH3 regions. Thus, improving antigen design and understanding the in vivo mechanisms that control the maturation of the B cell response with various vaccines should facilitate development of a successful HIV vaccine. The data obtained over this past year have shown the following; 1. Performed gene profiling of NHP that had been immunized with multiple different adjuvants with HIV env protein to determine the innate mechanisms which controlled antibody and CD4 T cell responses. A set of gene signatures was also shown to correlate with qualitative measures of antibody production including ADCC, Fc binding and patterns of glycosylation. 2. Adjuvant Development: Using novel synthetic polymers that could form particles in vivo in response to temperature or next generation polymers that can accommodate up to 128 attachment sites, studies were initiated to assess how HIV peptides and glycan peptides could be formulated to induced focused antibody responses to neutralizing sites on the HIV envelope. Agonists which activate toll like receptor 7 and 8 ligands were used to combine with these polymer-Env immunogens in mouse and NHP studies. 3. Made a series of novel peptide-glycan constructs for V3 directed anti-HIV antibody responses. These vaccines are used in conjunction with HIV Env trimers to try and focus the antibody response to specific V3 glycans.

Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
Zip Code
Liang, Frank; Lindgren, Gustaf; Sandgren, Kerrie J et al. (2017) Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci Transl Med 9:
Francica, Joseph R; Lynn, Geoffrey M; Laga, Richard et al. (2016) Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. Bioconjug Chem 27:2372-2385
Moody, M Anthony; Santra, Sampa; Vandergrift, Nathan A et al. (2014) Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. J Virol 88:3329-39
Feng, Yu; Forsell, Mattias N E; Flynn, Barbara et al. (2013) Chemical cross-linking of HIV-1 Env for direct TLR7/8 ligand conjugation compromises recognition of conserved antigenic determinants. Virology 446:56-65
Quinn, Kylie M; Yamamoto, Ayako; Costa, Andreia et al. (2013) Coadministration of polyinosinic:polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhances HIV gag-specific T cell immunity. J Immunol 191:5085-96
Quinn, Kylie M; Da Costa, Andreia; Yamamoto, Ayako et al. (2013) Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol 190:2720-35
Park, Haesun; Adamson, Lauren; Ha, Tae et al. (2013) Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates. J Immunol 190:4103-15
Johnson, Matthew J; Petrovas, Constantinos; Yamamoto, Takuya et al. (2012) Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. J Immunol 188:6109-18
Petrovas, Constantinos; Yamamoto, Takuya; Gerner, Michael Y et al. (2012) CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest 122:3281-94
Gujer, Cornelia; Sundling, Christopher; Seder, Robert A et al. (2011) Human and rhesus plasmacytoid dendritic cell and B-cell responses to Toll-like receptor stimulation. Immunology 134:257-69

Showing the most recent 10 out of 21 publications